The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 872 Weight Management articles
Severe ankle pain led Jelon Smart to Ozempic, where she dropped 30 pounds quickly—but plateaued until adding exercise. Doctors like Dafina Allen and Gerald Onuoha stress that GLP-1s alone aren't enough; movement, mental health, and monitored dosing are key for long-term success and safety.
More people are using GLP-1 injectables like Wegovy for weight management, but air travel poses refrigeration challenges. As a flight attendant, I've fielded countless requests to store meds in plane fridges—here's why that's not possible and the practical solutions that work.
The FDA just greenlit a groundbreaking higher dose of Wegovy, tripling the previous maximum to 7.2 milligrams for enhanced weight management. Patients saw up to 21% body weight loss, with unique cardiovascular protections. Here's what this means for obesity treatment and access.
GLP-1 medications are suppressing appetite, prompting users to prioritize protein quality over quantity—and dairy is ideally positioned to meet this demand, says Valio's innovation chief Dr. Kevin Deegan. At the Arena Dairy Innovation Strategies conference, experts discussed how these drugs change consumer perceptions of protein and sweetness. While some users revert to old habits post-treatment, dairy's natural, high-quality proteins offer a strategic advantage.
High demand for GLP-1 medications meets steep pricing and insurance hurdles. In this Q&A, eHealth's Whitney Stidom reveals why 55% of employers cover GLP-1s for diabetes but only 36% for weight loss, plus upcoming policy changes capping costs at $245 monthly for Medicare enrollees. Discover actionable insights on affordability and access.
After semaglutide's patent expired on March 20, over 40 Indian manufacturers launched 50+ generics, slashing prices up to 90%. Novo Nordisk, maker of Ozempic and Wegovy, is countering not with deep discounts but clinical data from 50+ trials and partnerships. Vikrant Shrotriya shares how this strategy aims to widen access while preserving quality.
GLP-1 therapies, including Ozempic (semaglutide) and Mounjaro (tirzepatide), have evolved from diabetes treatments to versatile options for weight management and cardiovascular health. While offering significant benefits like reduced appetite and vascular protection, they come with gastrointestinal side effects and rare serious risks. This guide evaluates their risks and rewards across conditions.
At a recent Pune meeting, experts from Pune and Mumbai underscored a holistic framework for Semaglutide use in weight management, especially as the drug goes off-patent in India. They stress pairing it with diet, exercise, and thorough patient assessments for lasting results in obesity and diabetes control. Generic versions now available for Rs 1,290 per month offer affordable access with proper precautions.
Telangana's Drugs Control Administration has issued a stark warning against misusing Semaglutide formulations for weight loss without medical oversight. With patent expiry looming in March 2026, multiple versions are flooding the market, raising safety concerns. Improper use risks serious complications like pancreatitis and gastrointestinal disorders.
